Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Gastrointestinal 2Thoracic 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acetylcysteine × Gynecologic × 1 year × Clear all
NCT04520139 2026-04-29

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

University of California, Irvine

Phase 1/2 Not yet recruiting
102 enrolled
Gynecologic

Chemotherapy-Related Cognitive Impairment, Ovarian Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡